It would have been a big trouble if no improvement

New registration of acquired medicines such as Celltrion and Organon Korea

By establishing a new regulation on the succession of drug prices for transfer and acquisition products, avoiding the application of stepwise application

Pharmaceutical companies are actively working on transferring drug copyrights.

 

As drug prices of transfer and transfer drugs are allowed, the transfer of permission rights due to mergers and acquisitions or corporate separation is speeding up.

 

It is trying to enter the new generic market by receiving expensive products from other companies.

 

According to the MOHW on the 7th, Celltrion's Actos 15mg will be newly listed on the health insurance benefit list at 626 won starting this month.

 

The copyright of Actos 15mg will be changed to Celltrionl.

 

Takeda Korea's Actos 15mg was removed from the list.

 

It is a follow-up measure to Celltrion's acquisition of Takeda's drugs.

 

Celltrion acquired Takeda's primary care division in the Asia-Pacific region for $278 million in June last year.

 

Takeda has all rights to patents, trademarks, and sales of 18 pharmaceutical products sold in Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.

 

In Korea, Celltrion will take over the rights of Takeda products acquired by Celltrion.

 

Celltrion is in the stage of completing the transfer of rights in Korea through the procedure of changing permission rights and registering drugs.

 

The price of Actos 15mg remains the same as the previous drug price of 626 won.

 

The previous upper limit of 626 won was maintained as the drug price succession rule was newly established in January.

 

If the right to Actos 15mg was changed last year, drug prices are likely to have fallen significantly.

 

Due to the reorganization of the drug price system in July last year, the drug price system was implemented, where the drug price fell as the registration time was delayed.

 

If there are more than 20 identical registered products, generic will have a 15% lower drug price.

 

At this time, the transfer drug was listed at the lowest price among the same products due to the application of the step-type drug price system.

 

If the drug license is changed, it goes through a procedure of deleting and re-registration.

 

Even if it was a previously registered product, it was inevitable to apply a step-type drug price system.

 

When the pharmaceutical industry pointed out that it was unfair to register transferred drugs in the same way as newly registered products, the MOHW accepted the improvement of the system improvement.

 

With the revision of the regulations, Actos was able to maintain the previous drug price of 626 won.

 

Singulair Chewable 4mg of Organon Korea has been listed at 693 won since this month.

 

As the license was changed to Organon, a new corporation spun off from MSD Korea, it was newly listed on the health insurance benefit list.

 

The 4mg Singular Chewable has 59 identical products listed.

 

If 4mg of Singular Chewable is recognized as a newly registered product, it cannot exceed 322 won.

 

As drug prices were allowed to succeed, drug prices avoided falling below half.

 

Organon's Vytorin 10/10 and Vytorin 10/20 were listed at 782 won and 1,093 won, respectively.

 

Vytorin 10/10 and Vytorin 10/20 each have 48 generics listed, so new licensed products are subject to the step-type drug price system.

 

If Vytorin 10/10 is applied as a newly registered product, it cannot exceed 481 won.

 

However, due to the improvement of the system, the previous drug price was applied as it was.